Biopharmaceutical analytical and bioanalytical contract solutions provider, SGS, has revealed it is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with a new 200 m2lab.
Geneva
The new lab will be equipped with a number of instruments to meet the increasing need for biopharmaceutical studies during the early and late phase of characterisation, as required by the ICH guidelines.
“To fulfil regulatory requirements, the biopharmaceutical industry increasingly expects its contract service providers to offer comprehensive characterisation capabilities from a single location,” explained Luc-Alain Savoy, managing director SGS Life Sciences Geneva. “SGS is committed to investing in its network of laboratories to offer integrated solutions and adapt to its clients’ local and global needs.”
The completed new lab is expected to open in Q3 this year and will complement the existing facility while also offering new services for high order structure analysis of biologics. These new services include circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).
Furthermore, the new lab will enable the Geneva facility to offer a full ICH Q6B physico-chemical characterisation of biological products.